42P Comparative real-world analysis of pembrolizumab plus chemo vs platinum-doublet alone in metastatic non-squamous NSCLC with PD-L1 low

Abstract

Following the introduction of immunotherapy (IO) as standard first-line (1L) treatment in patients (pts) affected by NSCLC without sensitizing EGFR or ALK mutations and PD-L1 (≥50%), increasing real-world data depict how difficult it is to replicate data from pivotal clinical trials to clinical practice, with high rates of early treatment failure. In the context of chemo-IO combo, our study aims to compare platinum-pemetrexed-pembrolizumab (PPP) combo to platinum-doublet alone in pts with low PD-L1 (<50%).